BioLineRx, Genentech, Roche deal

BioLineRx and Roche’s Genentech unit partnered to conduct Phase Ib trials evaluating BioLineRx’s BL-8040 plus Genentech’s Tecentriq atezolizumab. Genentech will conduct several trials in solid cancers, and BioLineRx will conduct a single trial in acute myelogenous leukemia (AML). Both parties have the option to expand the collaboration to include a registration trial. The trials are slated to begin in 1H17. ...